Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | mRNA-4359 |
| Trade Name | |
| Synonyms | mRNA 4359|mRNA4359 |
| Drug Descriptions |
mRNA-4359 is an mRNA-based cancer vaccine targeting IDO1 and PD-L1, which potentially increases T-cell response against tumor cells expressing PD-L1 and IDO1 (Ann Oncol (2024) 35 (Suppl_2): S521-S522). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C190738 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Ipilimumab + mRNA-4359 + Nivolumab | Ipilimumab Nivolumab mRNA-4359 | 0 | 1 |
| mRNA-4359 | mRNA-4359 | 0 | 1 |
| mRNA-4359 + Pembrolizumab | Pembrolizumab mRNA-4359 | 0 | 1 |